Table 1.
Clinical characteristics of newly diagnosed, untreated PD patients and RBD subjects.
| PD (n = 30) | RBD (n = 50) | |
|---|---|---|
| Mean Age (years) | 64.9 (SD 10.9, range 34–79) | 64.9 (SD 9.1, range 40–83) |
| Men | 70% (n = 21) | 82% (n = 41) |
| Women | 30% (n = 9) | 18% (n = 9) |
| Positive history of Parkinson’s disease in family | 7% (n = 2) | 2% (n = 1) |
| Mean age of disease onset (years) | 63.4 (SD 11.9, range 30–78) | 59.2 (SD 9.8, range 33–81) |
| Age of disease onset <40 years | 10% (n = 3) | 4% (n = 2) |
| Mean symptoms duration (years) | 1.6 (SD 1.3, range 0.5–6) | 5.8 (SD 4.4, range 1–17) |
| Mean Hoehn & Yahr score | 2.1 (SD 0.3, range 1.5–2.5) | n/a |
| Mean UPDRS III total | 20.2 (SD 12.4, range 6–54) | 5.2 (SD 4.1, range 0–21) |
| Mean UPDRS III 18 speech item | 0.4 (SD 0.5, range 0–1) | 0.06 (SD 0.24, range 0–1) |
| Antidepressant therapy | 10% (n = 3) | 14% (n = 7) |
| Antiparkinsonian therapy | 0 (n = 0) | 0 (n = 0) |
| Levodopa equivalent (mg/day) | 0 | 0 |
| Clonazepam therapy | 10% (n = 3) | 12% (n = 6) |
| Clonazepam (mg/day) | 0.07 (SD 0.22, range 0–1) | 0.08 (SD 0.30, range 0–2) |
Captions: PD = Parkinson’s disease, RBD = rapid eye movement sleep behaviour disorder, SD = standard deviation, n/a = not applicable.